Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Published on December 27, 2024

regarding its ability to fund ongoing operations into 2025, future expenses, capital requirements, and need for additional financing in the